** Shares of drug developer Mersana Therapeutics MRSN.O fall 5.5% to 34 cents premarket
** MRSN announces restructuring and reprioritization plan to extend its cash and for further development of its experimental cancer drug, emiltatug ledadotin
** Restructuring plan will reduce workforce by about 55% across functions, expected to be substantially be complete by end of Q3 2025, MRSN says
** Co to also reduce its research activities and eliminate internal pipeline development efforts
** These actions are expected to provide co with sufficient cash resources to support its current operating plan commitments into mid-2026, MRSN says
** Brokerage William Blair says given stock pullback, this creates an attractive entry point into the story and offers an opportunity to gain access to the experimental therapy
** Up to last close, stock down 74.5% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。